
Opinion|Videos|June 17, 2024
Understanding Differences in Fusion-Guided Biopsy Technologies
Experts on prostate cancer focus on the differences between fusion-guided technologies, highlighting cognitive-based and software-based fusions.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- When considering fusion-guided technologies, what is the difference between cognitive-based fusion and software-based fusion? What about rigid fusion and elastic fusion?
Advertisement
Related to this article

Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.

Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.

The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.

These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.

Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
3
Survey: Service members and veterans with NMIBC report barriers to treatment access
4
Q&A: Where ProACT fits in the male stress urinary incontinence algorithm
5



